<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
<meta http-equiv="Content-Type" content=
"text/html; charset=utf-8" /><!-- AppResources meta begin -->

<script type="text/javascript">
//<![CDATA[
var ncbi_startTime = new Date();
//]]>
</script><!-- AppResources meta end -->
<!-- TemplateResources meta begin -->
<meta name="paf_template" content="" />
<!-- TemplateResources meta end -->
<!-- Logger begin -->
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_pdid" content="article" />
<meta name="ncbi_acc" content="" />
<meta name="ncbi_domain" content="brjclinpharm" />
<meta name="ncbi_report" content="record" />
<meta name="ncbi_type" content="fulltext" />
<meta name="ncbi_objectid" content="" />
<meta name="ncbi_pcid" content="/articles/PMC1884989/" />
<meta name="ncbi_app" content="pmc" /><!-- Logger end -->
<title>Effects of cytochrome P450 3A modulators ketoconazole and
carbamazepine on quetiapine pharmacokinetics</title>
<!-- AppResources external_resources begin -->
<link rel="stylesheet" href="/core/jig/1.14.4/css/jig.min.css" />
<script type="text/javascript" src=
"/core/jig/1.14.4/js/jig.min.js">
</script><!-- AppResources external_resources end -->
<!-- Page meta begin -->
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" />
<link rel="canonical" href="/pmc/articles/PMC1884989/" />
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" />
<meta name="citation_journal_title" content=
"British Journal of Clinical Pharmacology" />
<meta name="citation_title" content=
"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics" />
<meta name="citation_authors" content=
"Scott W Grimm, Neil M Richtand, Helen R Winter, Karen R Stams, Stots B Reele" />
<meta name="citation_date" content="January 2006" />
<meta name="citation_issue" content="1" />
<meta name="citation_volume" content="61" />
<meta name="citation_firstpage" content="58" />
<meta name="citation_doi" content=
"10.1111/j.1365-2125.2005.02507.x" />
<meta name="citation_abstract_html_url" content=
"/pmc/articles/PMC1884989/?report=abstract" />
<meta name="citation_pmid" content="16390352" />
<meta name="DC.Title" content=
"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics" />
<meta name="DC.Type" content="Text" />
<meta name="DC.Publisher" content="Wiley-Blackwell" />
<meta name="DC.Contributor" content="Scott W Grimm" />
<meta name="DC.Contributor" content="Neil M Richtand" />
<meta name="DC.Contributor" content="Helen R Winter" />
<meta name="DC.Contributor" content="Karen R Stams" />
<meta name="DC.Contributor" content="Stots B Reele" />
<meta name="DC.Date" content="2006 Jan" />
<meta name="DC.Identifier" content=
"10.1111/j.1365-2125.2005.02507.x" />
<meta name="DC.Language" content="en" />
<meta property="og:title" content=
"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics" />
<meta property="og:type" content="article" />
<meta property="og:description" content=
"To explore the potential for drug interactions on quetiapine pharmacokinetics using in vitro and in vivo assessments.The CYP enzymes responsible for quetiapine metabolite formation were assessed using recombinant expressed CYPs and CYP-selective inhibitors. ..." />
<meta property="og:url" content=
"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884989/" />
<meta property="og:site_name" content="PubMed Central (PMC)" />
<meta property="og:image" content=
"http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" />
<meta name="twitter:card" content="summary" />
<meta name="twitter:site" content="@ncbi" />
<link rel="stylesheet" href="/corehtml/pmc/css/3.4/pmc.min.css"
type="text/css" />
<link rel="stylesheet" href=
"/corehtml/pmc/css/3.4/pmc_extras_prnt.min.css" type="text/css"
media="print" />
<script type="text/javascript" src=
"/corehtml/pmc/js/common.min.js">
//<![CDATA[
//
//]]>
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/NcbiTagServer.min.js">
//<![CDATA[
//
//]]>
</script>
<meta name="citationexporter" content=
"backend:'/pmc/utils/ctxp/'" />
<script type="text/javascript" src=
"/corehtml/pmc/ctxp/jquery.citationexporter.js">
//<![CDATA[
//
//]]>
</script>
<link rel="stylesheet" href=
"/corehtml/pmc/ctxp/citationexporter.css" type="text/css" />
<script type="text/javascript" src=
"/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js">
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/large-obj-scrollbars.min.js">
</script>
<script type="text/javascript">
//<![CDATA[
window.name="mainwindow";
//]]>
</script>
<style type="text/css">
/*<![CDATA[*/
.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-brjclinpharm.gif);background-size: auto, contain}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
.print-view{display:block}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
/*]]>*/
</style>
<link rel="alternate" type="application/epub+zip" href=
"/pmc/articles/PMC1884989/epub/" />
<link rel="alternate" type="application/pdf" href=
"/pmc/articles/PMC1884989/pdf/bcp0061-0058.pdf" />
<!-- Page meta end -->
<link rel="shortcut icon" href=
"//www.ncbi.nlm.nih.gov/favicon.ico" />
<meta name="ncbi_phid" content=
"F4FB70756FE7D131000000000067EB0A" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3852956/3985586/3808861/3734262/3974050/3917732/251717/4048120/3846471/14534/45193/3988413/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4052581/9685/3549676/3609192/3609193/3609213/3395586/3855312.css" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3411343/3882866/3929378.css"
media="print" />
</head>
<body class="article">
<div class="grid">
<div class="col twelve_col nomargin shadow">
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
<div class="sysmessages"><noscript>
<p class="nojs"><strong>Warning:</strong> The NCBI web site
requires JavaScript to function. <a href=
"/guide/browsers/#enablejs" title="Learn how to enable JavaScript"
target="_blank">more...</a></p>
</noscript></div>
<!--/.sysmessage-->
<div class="wrap">
<div class="page">
<div class="top">
<div class="universal_header" id="universal_header">
<ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id=
"navcontent">
<li class=
"ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt">
<a class="ui-ncbimenu-link-first" href="/" role="banner" title=
"NCBI Home" id="ncbihome" accesskey="1"><span class=
"offscreen_noflow">NCBI</span><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/28977"
class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#maincontent" title="Skip to the content" tabindex="0" accesskey=
"3">Skip to main content</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#navcontent" title="Skip to the navigation" tabindex="0"
accesskey="4">Skip to navigation</a></li>
<li id="resource-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset">
<a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href=
"/static/header_footer_ajax/submenu/#resources">Resources</a></li>
<li id="all-howtos-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first"><a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href="/static/header_footer_ajax/submenu/#howto">How To</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"/guide/browsers/#accesskeys" title="About My NCBI Accesskeys"
tabindex="0" accesskey="0">About NCBI Accesskeys</a></li>
</ul>
<div class="myncbi"><span id="myncbiusername" style=
"display:none"><a href="/account/settings/" id="mnu" title=
"Edit account settings"></a></span><a accesskey="2" href="/myncbi/"
id="myncbi" style="display:none">My NCBI</a><a href="/account/" id=
"sign_in">Sign in to NCBI</a><a href="/account/signout/" id=
"sign_out" style="display:none">Sign Out</a></div>
</div>
<div class="header">
<div class="res_logo">
<h1 class="img_logo"><a href="/pmc/" class=
"pmc_logo offscreen">PMC</a></h1>
<div class="NLMLogo"><a href="http://www.nlm.nih.gov/" title=
"US National Library of Medicine">US National Library of
Medicine</a><br />
<a href="http://www.nih.gov/" title=
"National Institutes of Health">National Institutes of
Health</a></div>
</div>
<div class="search">
<form method="get" action="/pmc/">
<div class="search_form"><label for="database" class=
"offscreen_noflow">Search database</label><select id="database">
<optgroup label="Recent">
<option value="pmc" selected="selected" class="last" data-ac_dict=
"pmc-search-autocomplete">PMC</option>
</optgroup>
<optgroup label="All">
<option value="gquery">All Databases</option>
<option value="assembly">Assembly</option>
<option value="bioproject">BioProject</option>
<option value="biosample">BioSample</option>
<option value="biosystems">BioSystems</option>
<option value="books">Books</option>
<option value="clinvar">ClinVar</option>
<option value="clone">Clone</option>
<option value="cdd">Conserved Domains</option>
<option value="gap">dbGaP</option>
<option value="dbvar">dbVar</option>
<option value="epigenomics">Epigenomics</option>
<option value="nucest">EST</option>
<option value="gene">Gene</option>
<option value="genome">Genome</option>
<option value="gds">GEO DataSets</option>
<option value="geoprofiles">GEO Profiles</option>
<option value="nucgss">GSS</option>
<option value="gtr">GTR</option>
<option value="homologene">HomoloGene</option>
<option value="medgen">MedGen</option>
<option value="mesh">MeSH</option>
<option value="ncbisearch">NCBI Web Site</option>
<option value="nlmcatalog">NLM Catalog</option>
<option value="nuccore">Nucleotide</option>
<option value="omim">OMIM</option>
<option value="pmc" data-ac_dict="pmc-search-autocomplete">
PMC</option>
<option value="popset">PopSet</option>
<option value="probe">Probe</option>
<option value="protein">Protein</option>
<option value="proteinclusters">Protein Clusters</option>
<option value="pcassay">PubChem BioAssay</option>
<option value="pccompound">PubChem Compound</option>
<option value="pcsubstance">PubChem Substance</option>
<option value="pubmed">PubMed</option>
<option value="pubmedhealth">PubMed Health</option>
<option value="snp">SNP</option>
<option value="sra">SRA</option>
<option value="structure">Structure</option>
<option value="taxonomy">Taxonomy</option>
<option value="toolkit">ToolKit</option>
<option value="toolkitall">ToolKitAll</option>
<option value="toolkitbook">ToolKitBook</option>
<option value="toolkitbookgh">ToolKitBookgh</option>
<option value="unigene">UniGene</option>
</optgroup>
</select>
<div class="nowrap"><label for="term" class="offscreen_noflow"
accesskey="/">Search term</label>
<div class="nowrap"><input type="text" name="term" id="term" title=
"Search PMC. Use up and down arrows to choose an item from the autocomplete."
value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config=
"dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'"
autocomplete="off" data-sbconfig=
"ds:'no',pjs:'no',afs:'yes'" /></div>
<button id="search" type="submit" class="button_search nowrap" cmd=
"go">Search</button></div>
</div>
</form>
<ul class="searchlinks inline_list">
<li><a href="/pmc/limits/">Limits</a></li>
<li><a href="/pmc/advanced/">Advanced</a></li>
<li><a href="/pmc/journals/">Journal list</a></li>
<li class="help"><a target="_blank" href=
"/books/NBK3825/">Help</a></li>
</ul>
</div>
</div>
<!--<component id="Page" label="headcontent"/>--></div>
<div class="content"><!-- site messages -->
<div class="container">
<div id="maincontent" class="content eight_col col">
<div class="navlink-box">
<ul class="page-breadcrumbs inline_list small">
<li class="journal-list"><a href="/pmc/journals/" class=
"navlink">Journal List</a></li>
<li class="archive-page"><a class="navlink" href=
"/pmc/journals/279/">Br J Clin Pharmacol</a></li>
<li class="issue-page"><a class="navlink" href=
"/pmc/issues/144700/">v.61(1); 2006 Jan</a></li>
<li class="accid">PMC1884989</li>
</ul>
</div>
<!-- Journal banner -->
<div class="pmc-page-banner whole_rhythm">
<div><img src="/corehtml/pmc/pmcgifs/logo-brjclinpharm.gif" alt=
"Logo of brjclinpharm" usemap="#logo-imagemap" /><map id=
"logo-imagemap" name="logo-imagemap">
<area alt="Link to Publisher's site" title=
"Link to Publisher's site" shape="default" coords="0,0,499,74"
href="http://www.blackwellpublishing.com/journal.asp?ref=0306-5251"
target="pmc_ext" ref=
"reftype=publisher&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" />
</map></div>
</div>
<!--component id='MainPortlet' label='search-reference'/-->
<!-- Book content -->
<div class="">
<div class=
"hide-overflow article lit-style content pmc-wm slang-all page-box">
<!--main-content-->
<div class="jig-ncbiinpagenav" data-jigconfig=
"smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'">
<div class="fm-sec half_rhythm no_top_margin">
<div class="fm-citation half_rhythm no_top_margin clearfix">
<div class="small">
<div class="inline_block eight_col va_top">
<div>
<div><span class="cit">Br J Clin Pharmacol. 2006 Jan; 61(1):
58–69.</span></div>
<div><span class="doi">doi:&nbsp; <a href=
"http://dx.doi.org/10.1111%2Fj.1365-2125.2005.02507.x" target=
"pmc_ext" ref=
"reftype=other&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">
10.1111/j.1365-2125.2005.02507.x</a></span></div>
</div>
</div>
<div class=
"inline_block four_col va_top show-overflow align_right">
<div class="fm-citation-ids">
<div class="fm-citation-pmcid"><span class=
"fm-citation-ids-label">PMCID:</span> <span>PMC1884989</span></div>
</div>
</div>
</div>
</div>
<h1 class="content-title">Effects of cytochrome P450 3A modulators
ketoconazole and carbamazepine on quetiapine pharmacokinetics</h1>
<div class="half_rhythm">
<div class="contrib-group fm-author"><a href=
"/pubmed/?term=Grimm%20SW%5Bauth%5D">Scott W Grimm</a>,<sup>1</sup>
<a href="/pubmed/?term=Richtand%20NM%5Bauth%5D">Neil M
Richtand</a>,<sup>2</sup> <a href=
"/pubmed/?term=Winter%20HR%5Bauth%5D">Helen R
Winter</a>,<sup>1</sup> <a href=
"/pubmed/?term=Stams%20KR%5Bauth%5D">Karen R Stams</a>,<sup>3</sup>
and <a href="/pubmed/?term=Reele%20SB%5Bauth%5D">Stots B
Reele</a><sup>1</sup></div>
</div>
<div class="fm-panel small half_rhythm">
<div class="fm-authors-info fm-panel hide half_rhythm" id=
"id846422_ai" style="display:none">
<div class="fm-affl" lang="en"><sup>1</sup>AstraZeneca
Pharmaceuticals LP, Wilmington, DE</div>
<div class="fm-affl" lang="en"><sup>2</sup>Department of
Psychiatry, Cincinnati Veterans Affairs Medical Center and
University of Cincinnati College of Medicine, Cincinnati, OH</div>
<div class="fm-affl" lang="en"><sup>3</sup>AstraZeneca
Pharmaceuticals LP, Boston, MA, USA</div>
<div id="cor1">Correspondence Scott W. Grimm PhD, AstraZeneca
Pharmaceuticals LP, 1800 Concord Pike, PO Box 15437, Wilmington, DE
19850, USA. Tel.: + 1 302 886 2271 Fax: + 1 302 886 5345 E-mail:
<a href="mailto:dev@null" data-email="moc.acenezartsa@mmirg.ttocs"
class="oemail">moc.acenezartsa@mmirg.ttocs</a></div>
</div>
<div class="togglers"><a href="#" class="pmctoggle" rid=
"id846422_ai">Author information <span>►</span></a> <a href="#"
class="pmctoggle" rid="id846422_an">Article notes
<span>►</span></a> <a href="#" class="pmctoggle" rid=
"id846422_cpl">Copyright and License information
<span>►</span></a></div>
<div class="fm-article-notes fm-panel hide half_rhythm" id=
"id846422_an" style="display:none">
<div class="fm-pubdate half_rhythm">Received 2004 Dec 21; Accepted
2005 May 25.</div>
</div>
<div class="fm-cpl-info fm-panel hide half_rhythm" id=
"id846422_cpl" style="display:none">
<div class="fm-copyright half_rhythm"><a href=
"/pmc/about/copyright.html">Copyright</a> © 2005 Blackwell
Publishing Ltd</div>
</div>
</div>
<div class="links-box fm-panel whole_rhythm">
<div class="small">
<div>This article has been <a href=
"/pmc/articles/PMC1884989/citedby/">cited by</a> other articles in
PMC.</div>
</div>
</div>
</div>
<div class="sec"></div>
<div id="__abstractid848829" lang="en" class="tsec sec">
<h2 class="head no_bottom_margin" id="__abstractid848829title">
Abstract</h2>
<!--article-meta-->
<div>
<div id="__sec1" class="sec sec-first">
<h3>Aims</h3>
<p id="__p1" class="p p-first-last">To explore the potential for
drug interactions on quetiapine pharmacokinetics using <em>in
vitro</em> and <em>in vivo</em> assessments.</p>
</div>
<div id="__sec2" class="sec">
<h3>Methods</h3>
<p id="__p2" class="p p-first-last">The CYP enzymes responsible for
quetiapine metabolite formation were assessed using recombinant
expressed CYPs and CYP-selective inhibitors. P-glycoprotein (Pgp)
transport was tested in MDCK cells expressing the human MDR1 gene.
The effects of CYP3A4 inhibition were evaluated clinically in 12
healthy volunteers that received 25 mg quetiapine before and after
4 days of treatment with ketoconazole 200 mg daily. To assess
CYP3A4 induction <em>in vivo</em>, 18 patients with psychiatric
disorders were titrated to steady-state quetiapine levels (300 mg
twice daily), then titrated to 600 mg daily carbamazepine for 2
weeks.</p>
</div>
<div id="__sec3" class="sec">
<h3>Results</h3>
<p id="__p3" class="p p-first-last">CYP3A4 was found to be
responsible for formation of quetiapine sulfoxide and N- and
O-desalkylquetiapine and not a Pgp substrate. In the clinical
studies, ketoconazole increased mean quetiapine plasma
<em>C</em><sub>max</sub> by 3.35-fold, from 45 to 150 ng
ml<sup>−1</sup> (mean <em>C</em><sub>max</sub> ratio 90% CI 2.51,
4.47) and decreased its clearance (Cl/F) by 84%, from 138 to 22 l
h<sup>−1</sup> (mean ratio 90% CI 0.13, 0.20). Carbamazepine
decreased quetiapine plasma <em>C</em><sub>max</sub> by 80%, from
1042 to 205 ng ml<sup>−1</sup> (mean <em>C</em><sub>max</sub> ratio
90% CI 0.14, 0.28) and increased its clearance 7.5-fold, from 65 to
483 l h<sup>−1</sup> (mean ratio 90% CI 6.04, 9.28).</p>
</div>
<div id="__sec4" class="sec sec-last">
<h3>Conclusions</h3>
<p id="__p4" class="p p-first-last">Cytochrome P450 3A4 is a
primary enzyme responsible for the metabolic clearance of
quetiapine. Quetiapine pharmacokinetics were affected by
concomitant administration of ketoconazole and carbamazepine, and
therefore other drugs and ingested natural products that strongly
modulate the activity or expression of CYP3A4 would be predicted to
change exposure to quetiapine.</p>
</div>
</div>
<div class="sec"><strong class="kwd-title">Keywords:</strong>
<span class="kwd-text">carbamazepine, drug interaction,
ketoconazole, pharmacokinetics, quetiapine</span></div>
</div>
<div id="__sec5" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec5title">
Introduction</h2>
<p id="__p5" class="p p-first">Quetiapine fumarate, a
dibenzothiazepine psychotropic, is extensively metabolized <em>in
vivo</em> via sulfoxidation, considered the major metabolic
pathway, as well as oxidation to carboxylic acid, hydroxylation,
and dealkylation (<a href="/pmc/articles/PMC1884989/figure/fig01/"
target="figure" class="fig-table-link fig figpopup" rid-figpopup=
"fig01" rid-ob="ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure
1</span></a>) [<a href="#b1" rid="b1" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210926">1</a>–<a href="#b3" rid="b3" class=
" bibr popnode">3</a>]. Quetiapine is often used in combination
with other drugs; thus, an understanding of its potential for
clinically significant drug–drug interactions is essential to
successful therapy [<a href="#b4" rid="b4" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210949">4</a>–<a href="#b7" rid="b7" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210937">7</a>].</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig01"
co-legend-rid="lgnd_fig01"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC1884989/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01"><img src=
"/pmc/articles/PMC1884989/bin/bcp0061-0058-f1.gif" class=
"small-thumb" alt="Figure 1" title="Figure 1" src-large=
"/pmc/articles/PMC1884989/bin/bcp0061-0058-f1.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig01">
<div><a class="figpopup" href=
"/pmc/articles/PMC1884989/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01">Figure 1</a></div>
<!--caption a4-->
<div><span>Quetiapine and its principal metabolites in human liver
microsomes. A carboxylic acid metabolite found <em>in vivo</em> was
not detected in the microsomal incubates</span></div>
</div>
</div>
<p id="__p6" class="p p-last">A combination of commonly used <em>in
vitro</em> approaches, including metabolism by recombinant human
cytochrome P450 (CYP) and enzyme selective inhibitors in human
liver microsomes [<a href="#b8" rid="b8" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_130210927">8</a>,
<a href="#b9" rid="b9" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210945">9</a>], enabled identification of the CYP enzymes
that catalyse the formation of the primary circulating metabolites
of quetiapine. Based on these <em>in vitro</em> results, we
assessed the effects of ketoconazole, a strong CYP3A4 inhibitor,
and carbamazepine, a strong CYP3A4 inducer, on the pharmacokinetics
of quetiapine in healthy men and psychiatric patients,
respectively.</p>
</div>
<div id="__sec6" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec6title">Methods</h2>
<div id="__sec7" class="sec sec-first">
<h3><em>In vitro</em> studies of quetiapine metabolism</h3>
<div id="__sec8" class="sec sec-first-last">
<h4>Materials</h4>
<p id="__p7" class="p p-first">Unlabelled and
<sup>14</sup>C-labelled quetiapine (specific activity 52.1 Ci
mg<sup>−1</sup>), all unlabelled quetiapine metabolites,
dehydronifedipine and dextrorphan were synthesized by Zeneca
Pharmaceuticals (now AstraZeneca Pharmaceuticals LP, Macclesfield,
UK, and Wilmington, DE, USA). Phenacetin, acetaminophen,
ketoconazole and nifedipine used <em>in vitro</em> were reference
standards obtained from the US Pharmacopeial Convention, Inc.
(Rockville, MD, USA). S-mephenytoin, 4-hydroxymephenytoin,
hydroxytolbutamide, sulfaphenazole and furafylline were obtained
from Ultrafine Ltd (Manchester, UK). Diethyldithiocarbamate (DDC)
was purchased from Aldrich Chemical Company, Inc. (Milwaukee, WI,
USA). Tolbutamide, chlorpropamide, quinidine, nicotinamide adenine
dinucleotide phosphate (NADPH) and all other reagents were
purchased from Sigma Chemical Co. (St Louis, MO, USA) or other
standard sources. Fresh or snap-frozen human liver tissues were
obtained from the International Institute for the Advancement of
Medicine (Jessup, PA, USA).</p>
<p id="__p8" class="p p-last">Liver microsomes were prepared by
three-step differential centrifugation, as described previously
[<a href="#b10" rid="b10" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210939">10</a>], and stored at −70 °C. Microsomal protein
content was assayed using bicinchoninic acid reagent (Pierce
Chemical Co., Rockford, IL, USA) with bovine serum albumin as the
protein standard. Microsomes were pooled from several individual
donors by combining an equivalent amount of microsomal protein from
each sample. The complementary deoxyribonucleic acid-derived
expressed human CYP isoforms were obtained from Gentest Corporation
(Woburn, MA, USA).</p>
</div>
</div>
<div id="__sec9" class="sec">
<h3>Identification and kinetics of quetiapine metabolites formed by
human liver microsomes</h3>
<p id="__p9" class="p p-first">For <em>in vitro</em> identification
of quetiapine metabolites, human liver microsomes (1 mg protein
ml<sup>−1</sup>) were incubated for 60 min at 37 °C with 50
µ<span class="small-caps">m</span><sup>14</sup>C-quetiapine in 2.0
ml of assay buffer [50 m <span class="small-caps">m</span>
N-[2-hydroxyethyl]piperazine N-[2-ethanesulphonic acid] (HEPES), pH
7.6, containing 5 m <span class="small-caps">m</span>
MgCl<sub>2</sub> and 1 m <span class="small-caps">m</span>
NADPH].</p>
<p id="__p10">Parent compound and metabolites were extracted with
ethyl acetate after making the incubation mixture basic with
NH<sub>4</sub>OH. The organic layer was isolated and evaporated
under nitrogen. The extracted metabolites were redissolved in the
high-pressure liquid chromatography (HPLC) mobile phase (see below)
and subjected to liquid chromatography with mass spectrometric
detection. All <em>in vitro</em> extracts (50 µl) were separated
using a Zorbax SB-C8 4.6 × 25 mm column and a precolumn with the
same packing. The HPLC mobile phase consisted of 0.1% aqueous
trifluoroacetic acid (adjusted to pH 3.0 with NH<sub>4</sub>OH) and
100% acetonitrile, with gradient elution between 80 : 20 (v/v) and
65 : 35 (v/v) at 1.5 ml min<sup>−1</sup> over 30 min. Authentic
metabolite standards were analysed under the same conditions.</p>
<p id="__p11" class="p p-last">The kinetics of quetiapine
metabolite formation were similarly evaluated. Duplicate samples of
pooled microsomes (1 mg protein ml<sup>−1</sup>) were incubated for
20 min at 37 °C with <sup>14</sup>C-quetiapine (5–100 µ<span class=
"small-caps">m</span>) in 0.25 ml of the same assay buffer. After
incubation, the reaction was terminated by precipitation of the
microsomal protein by addition of acetonitrile. Quetiapine
metabolites formed in the mixture were separated by gradient
reverse-phase HPLC (described above) and monitored using both
solid-phase radiochemical and ultraviolet-photodiode array
detection. Peak areas of each metabolite in the chromatograms were
plotted against the initial concentration of quetiapine in the
incubations. Enzyme kinetic parameters for formation of each
quetiapine metabolite were calculated by using nonlinear regression
(PCNonlin; SCI Software, Lexington, KY, USA).</p>
</div>
<div id="__sec10" class="sec">
<h3>Effect of specific CYP inhibitors on quetiapine metabolism in
human liver microsomes</h3>
<p id="__p12" class="p p-first">Quetiapine (15 µ<span class=
"small-caps">m</span>) was coincubated with selective CYP
inhibitors at 37 °C with human liver microsomes (1 mg protein
ml<sup>−1</sup>) in assay buffer as described. A concentration of
15 µ<span class="small-caps">m</span> of quetiapine was used in
these experiments because it was well below the
apparent<em>K</em><sub><em>m</em></sub> values for metabolite
formation in human liver microsomes but allowed for analytical
detection of the metabolites formed, even though this concentration
is approximately sevenfold greater than the steady-state plasma
maximal drug concentration (<em>C</em><sub>max</sub>) following a
clinically used 300-mg twice-daily dose [<a href="#b11" rid="b11"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210934">11</a>].</p>
<p id="__p13" class="p p-last">The CYP inhibitors included
furafylline, sulfaphenazole, quinidine, DDC and ketoconazole, which
selectively inhibit CYP1A2, CYP2C9, CYP2D6, CYP2E1 and CYP3A4,
respectively. The amount of quetiapine metabolites formed in the
presence of these specific inhibitors was compared with a control
sample containing only quetiapine, microsomes, other reaction
cofactors, and solvent vehicle assay buffer (no inhibitor).</p>
</div>
<div id="__sec11" class="sec">
<h3>Quetiapine metabolism by heterologously expressed human CYP
enzymes</h3>
<p id="__p14" class="p p-first-last">Quetiapine (15 µ<span class=
"small-caps">m</span>) was incubated for 1 h at 37 °C in assay
buffer (as described above) containing microsomal fractions
isolated from human lymphoblastoid cell lines expressing CYP1A2,
CYP2C9, CYP2C19, CYP2D6 and CYP3A4. Exogenous CYP reductase (0.5 U
ml<sup>−1</sup>) was added to incubations containing CYP1A2 and
CYP2C19 because reductase was not coexpressed with CYP in these
cell lines. Control samples were prepared by coincubating
quetiapine with vector-transfected microsomal fractions lacking
expressed CYP protein.</p>
</div>
<div id="__sec12" class="sec">
<h3>Transport of quetiapine across MDR-1-MDCK cell monolayers</h3>
<p id="__p15" class="p p-first-last">Madin-Darby canine kidney
cells transfected with human multidrug resistance gene (MDR-1-MDCK
cells) were obtained from the Netherlands Cancer Institute
(Amsterdam, the Netherlands) and cultured in DMEM supplemented with
10% fetal bovine serum. Directional [basolateral to apical (B–A)
and apical to basolateral (A–B)] assays were conducted 3 days after
seeding MDR-1-MDCK cells onto polycarbonate Transwell membranes at
a density of 1.5 × 10<sup>6</sup> cm<sup>−2</sup>. Transport assays
were conducted with 1 µ<span class="small-caps">m</span> quetiapine
or the known P-glycoprotein (Pgp) substrate loperamide at 37 °C for
60 min. After incubation, samples from both the donor and receiver
chambers were analysed for quetiapine or loperamide concentration
using LC/MS/MS.</p>
</div>
<div id="__sec13" class="sec">
<h3>Clinical studies of the effects of ketoconazole and
carbamazepine on quetiapine pharmacokinetics</h3>
<p id="__p16" class="p p-first-last">Two clinical studies were
conducted to assess the effects of coadministration of drugs that
strongly induce or inhibit CYP3A4 on quetiapine pharmacokinetics.
In study 1, the effects of the CYP3A4 inhibitor ketoconazole were
examined in healthy volunteers. In study 2, the effects of the
CYP3A4 inducer carbamazepine were examined in patients. The
patients were diagnosed by their treating physician based on
Diagnostic and Statistical Manual of Mental Disorders, 4th edition,
Text Revision (DSM-IV-TR) criteria [<a href="#b12" rid="b12" class=
" bibr popnode">12</a>]. In both studies, pharmacokinetic
parameters obtained when quetiapine was used alone were compared
with those obtained after coadministration with ketoconazole or
carbamazepine.</p>
</div>
<div id="__sec14" class="sec">
<h3>Study participants</h3>
<p id="__p17" class="p p-first">Healthy male volunteers aged 24–42
years were enrolled in study 1. Exclusion criteria included a
positive test for hepatitis B surface antigen or human
immunodeficiency virus (HIV) antibody; abnormalities in baseline
laboratory values or electrocardiographic findings; presence of an
acute nonpsychiatric illness within 2 weeks before enrolment; and
use of drugs that affect the CYP enzyme system within 6 weeks
before study initiation. Study participants were asked to limit
their caffeine intake and refrain from making major changes in
their dietary habits throughout the study. Use of prescription and
nonprescription medications was prohibited unless deemed
appropriate by the investigator.</p>
<p id="__p18">Patients in study 2 were men and women aged 29–63
years; met DSM-IV-TR criteria [<a href="#b12" rid="b12" class=
" bibr popnode">12</a>] for schizophrenia, schizoaffective
disorder, or bipolar disorder; and were in remission from an acute
exacerbation of their disorder for at least 3 months. All patients
had been treated with antipsychotic medications during the year
before enrolment and were in remission without psychotic symptoms
at time of enrolment into the study. Some subjects had adverse
events on their previous medications, and because of the lower
incidence of dystonic movements on quetiapine, were considered to
be eligible and good candidates to be switched to quetiapine. The
subjects were withdrawn from any previous medication and started on
quetiapine within 4 days of their last dose of previous
antischizophrenic treatment, and were titrated to a high dose of
quetiapine (300 mg twice per day). The high dose ensured that even
with the enzyme induction secondary to carbamazepine, the subjects
would be receiving effective exposures to quetiapine. The subjects
all were inpatients during the study and were closely observed so
that if there was any sign of relapse of the acute psychotic state,
the carbamazepine would be terminated and the subject aggressively
treated. During the study none of the subjects had an acute relapse
of their psychosis (see clinical effect in the Results
section).</p>
<p id="__p19">Patients taking lithium for schizoaffective disorder
or bipolar disorder were allowed to continue doing so if their dose
had been stable for at least 1 month before enrollment. All other
antipsychotic, psychotropic or mood-stabilizing medications except
lithium were discontinued at enrolment. Only oral chloral hydrate
and benztropine mesylate were permitted to treat agitation,
insomnia or extrapyramidal symptoms. Acetaminophen was the only
analgesic allowed throughout the study. Women of childbearing age
were allowed to participate only if they were not pregnant and were
using a reliable nonhormonal method of contraception. Exclusions
included a DSM-IV-TR Axis I disorder other than schizophrenia,
schizoaffective disorder, or bipolar disorder; a positive test for
hepatitis B surface antigen or HIV antibody; presence of an acute
nonpsychiatric illness during the 2 weeks before study entry; use
of clozapine within 2 months of enrolment; or use of CYP inducers
or inhibitors within 6 weeks of enrolment.</p>
<p id="__p20" class="p p-last">The study in healthy volunteers was
conducted at Christiana Care Research Institute in Newark, Delaware
and was approved by the Institutional Review Board of Christiana
Care Health Services. The patient study was conducted at two sites:
Cincinnati VA Hospital and BHC Alhambra Hospital, Rosemead,
California. The University of Cincinnati Medical Center
Institutional Review Board and the Western Institutional Review
Board approved the study, and the study protocol adhered to the
ethical guidelines of the Declaration of Helsinki. Each subject
gave informed consent. At the time of enrollment into the study,
all of the patients were in remission, without active psychotic
behaviour and were judged by the investigator to be capable of
giving informed consent.</p>
</div>
<div id="__sec15" class="sec">
<h3>Study design</h3>
<p id="__p21" class="p p-first">Study 1 was an 8-day, open-label,
crossover trial in volunteers who resided at the clinical research
centre during the study. After an 8-h fast, study participants were
given a single oral dose of quetiapine (25 mg) at 08.00 h on days 1
and 6. Single oral doses of ketoconazole (200 mg day<sup>−1</sup>)
were administered at 06.00 h from day 3 through day 6. Ketoconazole
was taken at least 1 h before or 2 h after meals (quetiapine was
administered after fasting), with a 2-h interval between the doses
of ketoconazole and quetiapine on day 6.</p>
<p id="__p22" class="p p-last">Study 2 was a 36-day, open-label,
multicentre, multiple-dose, pharmacokinetic study. Quetiapine was
initiated at 25 mg twice daily on day 1 and increased to 300 mg
twice daily by day 5. Patients remained on this dose through day 33
and then discontinued treatment after a final 300-mg dose given on
the morning of day 34. Carbamazepine was initiated with a 200-mg
dose on the evening of day 9, continued at 200 mg twice daily on
days 10 through 12, and increased to 200 mg three times daily on
days 13 through 33, ending after a final 200-mg dose on the morning
of day 34. To attain a reliable determination of steady-state
trough plasma concentrations of quetiapine both before and after
the addition of carbamazepine, efforts were made to maintain a
precise 12-h interval between the morning and evening doses of
quetiapine on days 7 through 9 and days 32–33.</p>
</div>
<div id="__sec16" class="sec">
<h3>Pharmacokinetic sampling</h3>
<p id="__p23" class="p p-first">In study 1, blood samples were
obtained on days 1 and 6 at baseline and at 0.25, 0.5, 0.75, 1,
1.5, 2, 3, 5, 8, 12, 16, 20, 24 and 30 h after quetiapine
administration to measure concentrations of quetiapine and its
sulfoxide metabolite.</p>
<p id="__p24">In study 2, blood samples were obtained for
measurement of quetiapine exposure on days 9 and 34 at 15 min
before and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 h
after the morning dose of quetiapine. Additional blood samples were
taken 15 min before carbamazepine administration on the evening of
day 9 and the morning of day 34.</p>
<p id="__p25">In both studies, blood samples were collected into
heparinized Vacutainer® tubes (BD, Franklin Lakes, NJ, USA). The
blood was centrifuged within 15–30 min after collection, and the
resulting plasma samples were placed into polypropylene tubes and
frozen at −20 °C until analysed using HPLC with atmospheric
pressure chemical ionization and tandem mass spectrometry.</p>
<p id="__p26" class="p p-last">Plasma samples were analysed for
concentrations of quetiapine and its major metabolite, quetiapine
sulfoxide, using a validated procedure (KeyStone Analytical
Laboratories, Inc., North Wales, PA, USA). These analytes were
extracted from alkalinized plasma with ethyl acetate and
evaporated, and the dried residues reconstituted in 50 : 50
methanol:acetonitrile. Chromatographic separation was carried out
on a reverse-phase liquid chromatography system utilizing a 3.5-µm
Zorbax™ SB-phenyl (4.6 × 75 mm) column, with a mobile phase
composed of 0.088% ammonium formate (pH 3.0), methanol and
acetonitrile at a flow rate of 1.5 ml min<sup>−1</sup>. Detection
was achieved on a PE Sciex API 300 tandem mass spectrometer with
turbo ionspray ionization. The parent/daughter ions monitored were
m/z 384.2/253.0 (quetiapine) and m/z 400.1/221.1 (sulfoxide
metabolite). The method has a quantification range of 2.50–500 ng
ml<sup>−1</sup> with an applicable range to 5000 ng ml<sup>−1</sup>
by sample dilution with plasma.</p>
</div>
<div id="__sec17" class="sec">
<h3>Pharmacokinetic variables</h3>
<p id="__p27" class="p p-first">In study 1, primary pharmacokinetic
variables included the area under the plasma concentration–time
curve from baseline to <em>t</em> hours after dosing
(AUC<sub>0–<em>t</em></sub>), the total area under the plasma
concentration–time curve from time 0 to infinity (AUC), and
<em>C</em><sub>max</sub>. The terminal half-life
(<em>t</em><sub>1/2</sub>) and apparent oral clearance (CL/F) of
quetiapine were evaluated as secondary pharmacokinetic parameters.
The pharmacokinetic profile of the sulfoxide metabolite of
quetiapine was also examined.</p>
<p id="__p28">In study 2, all primary pharmacokinetic parameters
were assessed at steady state (ss), confirmed by analysis of
minimum plasma concentrations (<em>C</em><sub>min</sub>).
Parameters included <em>C</em><sub>max</sub>-ss and AUCτ-ss, where
τ is the dosing interval. Secondary pharmacokinetic parameters
included time to reach <em>C</em><sub>max</sub>-ss
(<em>t</em><sub>max</sub>-ss), <em>C</em><sub>min</sub>-ss and
CL/F.</p>
<p id="__p29" class="p p-last">In both studies, all pharmacokinetic
parameters were determined using a noncompartmental model.</p>
</div>
<div id="__sec18" class="sec sec-last">
<h3>Statistical analyses</h3>
<p id="__p30" class="p p-first">In study 1,
AUC<sub>0–<em>t</em></sub>, AUC, <em>C</em><sub>max</sub> and CL/F
were logarithmically transformed before analysis of variance
(<span class="small-caps">anova</span>). The 90% confidence
intervals of the geometric mean ratio for day 6 to day 1 for these
parameters were constructed using Schuirmann's two one-sided tests
procedure. The apparent <em>t</em>1/2 was analysed in a similar
fashion but not log transformed. Descriptive statistics were given
for all analyses of ketoconazole.</p>
<p id="__p31" class="p p-last">In study 2, the logarithmically
transformed values of AUCτ-ss, <em>C</em><sub>max</sub>-ss and CL/F
and the rank transformed values of <em>t</em><sub>max</sub>-ss on
day 9 (quetiapine alone) and day 34 (quetiapine plus carbamazepine)
were analysed using a two-way <span class=
"small-caps">anova</span>. The <span class=
"small-caps">anova</span> results were then used to construct 90%
confidence intervals for the geometric mean ratios of AUCτ-ss,
<em>C</em><sub>max</sub>-ss and CL/F. The interaction of quetiapine
and carbamazepine was assessed using the two one-sided tests
procedure. If the 90% confidence interval for a given geometric
mean ratio was between 0.8 and 1.25 (indicating a change of less
than 20% between day 9 and day 34), no statistically significant
interactions were recorded. To ensure achievement of steady state,
a two-way <span class="small-caps">anova</span> was used to compare
<em>C</em><sub>min</sub> values for quetiapine and its metabolites
on days 8 and 9 with values on days 33 and 34.</p>
</div>
</div>
<div id="__sec19" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec19title">Results</h2>
<div id="__sec20" class="sec sec-first">
<h3>In vitro <em>studies</em></h3>
<div id="__sec21" class="sec sec-first">
<h4>Quetiapine metabolites formed by human liver microsomes</h4>
<p id="__p32" class="p p-first-last">Four primary metabolites of
quetiapine oxidation – quetiapine sulfoxide, 7-hydroxyquetiapine,
and the N- and O-dealkylated products – were formed after
quetiapine incubation with human liver microsomes (<a href=
"/pmc/articles/PMC1884989/figure/fig02/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob=
"ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>).
Structures of metabolites were verified by using mass spectrometry
and by their retention times on HPLC in comparison with authentic
metabolite standards. The apparent <em>K</em><sub><em>m</em></sub>
values for the microsomal formation of quetiapine sulfoxide and the
7-hydroxy, N-desalkyl and O-desalkyl metabolites were estimated at
110, 160, 100, and 170 µ<span class="small-caps">m</span> (no
assessment of nonspecific microsomal binding as a correction
factor), respectively, although the maximum velocity of metabolite
formation (<em>V</em><sub>max</sub>) was not achieved for the four
reactions at quetiapine concentrations up to 100 µ<span class=
"small-caps">m</span> (the maximum concentration tested).</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig02"
co-legend-rid="lgnd_fig02"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC1884989/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02"><img src=
"/pmc/articles/PMC1884989/bin/bcp0061-0058-f2.gif" class=
"small-thumb" alt="Figure 2" title="Figure 2" src-large=
"/pmc/articles/PMC1884989/bin/bcp0061-0058-f2.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig02">
<div><a class="figpopup" href=
"/pmc/articles/PMC1884989/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02">Figure 2</a></div>
<!--caption a4-->
<div><span>(A) Chromatographic profile of quetiapine metabolites
formed during incubation with pooled human liver microsomes. (B)
Chromatographic profile of quetiapine metabolites formed during
incubation with recombinant expressed CYP3A4. AU, Absorbance
units</span></div>
</div>
</div>
</div>
<div id="__sec22" class="sec">
<h4>Inhibition of quetiapine metabolism by specific CYP isoenzyme
inhibitors</h4>
<p id="__p33" class="p p-first">Decreases in quetiapine metabolite
formation were observed after coincubation with CYP2C9, CYP2D6 and
CYP3A4 inhibitors (<a href="/pmc/articles/PMC1884989/table/tbl1/"
target="true" class="fig-table-link table figpopup" rid-figpopup=
"tbl1" rid-ob="ob-tbl1" co-legend-rid=""><span>Table 1</span></a>).
Ketoconazole, a CYP3A4 inhibitor, decreased the microsomal
formation of the sulfoxide metabolite in a concentration-dependent
manner, with greater than 50% inhibition achieved at 0.02
µ<span class="small-caps">m</span> ketoconazole. Ketoconazole also
decreased the formation of N- and O-desalkyl metabolites in a
concentration-dependent manner, whereas the 7-hydroxylation pathway
was not changed by more than 10% in a concentration-independent
fashion. The substantial inhibition of sulfoxidation and O- and
N-dealkylation pathways by ketoconazole indicated that CYP3A4
enzymes are primarily responsible for three of the four metabolic
pathways for quetiapine measured in human liver microsomes.</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl1"><a href="/pmc/articles/PMC1884989/table/tbl1/" target=
"table" rid-ob="ob-tbl1" rid-figpopup="tbl1" class=
"table img_link icnblk_img figpopup"><img alt="Table 1" title=
"Table 1" class="small-thumb" src=
"/pmc/articles/PMC1884989/table/tbl1/?report=thumb" src-large=
"/pmc/articles/PMC1884989/table/tbl1/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC1884989/table/tbl1/" target="table" rid-figpopup=
"tbl1" rid-ob="ob-tbl1">Table 1</a></div>
<!--caption a4-->
<div><span>Effect of specific CYP inhibitors on quetiapine
metabolism in human liver microsomes</span></div>
</div>
</div>
<p id="__p34">Quinidine, a potent inhibitor of CYP2D6, had no
effect on the formation of the sulfoxide or dealkylated metabolites
of quetiapine. However, 0.2–5 µ<span class="small-caps">m</span>
quinidine decreased formation of 7-hydroxyquetiapine by more than
50%, suggesting that CYP2D6 may be involved in 7-hydroxyquetiapine
formation [<a href="#b8" rid="b8" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210930">8</a>].</p>
<p id="__p35" class="p p-last">Sulfaphenazole, a selective CYP2C9
inhibitor, reduced formation of all four quetiapine metabolites
when coincubated in human liver microsomes at a high concentration
(100 µ<span class="small-caps">m</span>). However, at 5.0
µ<span class="small-caps">m</span>, a concentration that
substantially decreases the metabolism of known CYP2C9 substrates
[<a href="#b8" rid="b8" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210936">8</a>], sulfaphenazole had little effect on
quetiapine metabolism. Microsomal coincubation with furafylline (up
to 25 µ<span class="small-caps">m</span>) and DDC (up to 100
µ<span class="small-caps">m</span>), inhibitors of CYP1A2 and
CYP2E1, had little effect on quetiapine metabolism.</p>
</div>
<div id="__sec23" class="sec">
<h4>Quetiapine metabolism by heterologously expressed human CYP
isoenzymes</h4>
<p id="__p36" class="p p-first">Quetiapine metabolites were not
detected after 1-h incubations of quetiapine with microsomes from
vector-control lymphoblastoid cell lines or those that expressed
CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profiles
produced when quetiapine was incubated in human liver microsomes
(<a href="/pmc/articles/PMC1884989/figure/fig02/" target="figure"
class="fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob=
"ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2A</span></a>)
were similar to those produced by expressed CYP3A4 (<a href=
"/pmc/articles/PMC1884989/figure/fig02/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob=
"ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2B</span></a>).
Quetiapine sulfoxide was the major metabolite formed during
incubations with expressed CYP3A4. The O- and N-desalkyl
metabolites and detectable amounts of the 7-hydroxy metabolite also
were formed by expressed CYP3A4. Small amounts of a secondary
O-desalkylsulfoxide metabolite were identified in both human liver
microsomes and expressed CYP3A4. These findings clearly implicate
CYP3A4 as the major CYP involved in quetiapine metabolism.</p>
<p id="__p37" class="p p-last">Expressed CYP2D6 formed detectable
amounts of 7-hydroxyquetiapine but no other quetiapine metabolites.
This result further corroborated the inhibition of this pathway in
liver microsomes by the CYP2D6 inhibitor quinidine and confirmed
that CYP2D6 is at least partially responsible for quetiapine
7-hydroxylation.</p>
</div>
<div id="__sec24" class="sec sec-last">
<h4>Transport of quetiapine across MDR-1-MDCK cell monolayers</h4>
<p id="__p38" class="p p-first-last">The results of the experiments
on transport of quetiapine across MDR-1-MDCK cell monolayers
expressing human Pgp are shown in <a href=
"/pmc/articles/PMC1884989/table/tbl2/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl2" rid-ob=
"ob-tbl2" co-legend-rid=""><span>Table 2</span></a>. Quetiapine was
highly permeable in MDR-1-MDCK cell monolayers when incubated in
either the apical-to-basolateral or basolateral-to-apical
direction. There was little difference in flux in either direction
(flux ratio =1.2), indicating that quetiapine is not an efflux
substrate of Pgp.</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl2"><a href="/pmc/articles/PMC1884989/table/tbl2/" target=
"table" rid-ob="ob-tbl2" rid-figpopup="tbl2" class=
"table img_link icnblk_img figpopup"><img alt="Table 2" title=
"Table 2" class="small-thumb" src=
"/pmc/articles/PMC1884989/table/tbl2/?report=thumb" src-large=
"/pmc/articles/PMC1884989/table/tbl2/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC1884989/table/tbl2/" target="table" rid-figpopup=
"tbl2" rid-ob="ob-tbl2">Table 2</a></div>
<!--caption a4-->
<div><span>Transport of quetiapine (1 µ<span class=
"small-caps">m</span>) across MDR-1-MDCK cell
monolayers</span></div>
</div>
</div>
</div>
</div>
<div id="__sec25" class="sec sec-last">
<h3>Clinical studies</h3>
<div id="__sec26" class="sec sec-first">
<h4>Demographics</h4>
<p id="__p39" class="p p-first-last">In study 1, 12 healthy men
(mean age 33 years) were enrolled. All study participants completed
the trial and were included in the pharmacokinetic analysis. In
study 2, 18 patients (men and women; mean age 44 years) were
enrolled. Patients had diagnoses of paranoid schizophrenia
(<em>n</em> = 4) or schizoaffective (<em>n</em> = 6) or bipolar
disorder (<em>n</em> = 8). Fourteen patients had complete
pharmacokinetic data. Baseline demographics for both studies are
summarized in <a href="/pmc/articles/PMC1884989/table/tbl3/"
target="true" class="fig-table-link table figpopup" rid-figpopup=
"tbl3" rid-ob="ob-tbl3" co-legend-rid=""><span>Table
3</span></a>.</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl3"><a href="/pmc/articles/PMC1884989/table/tbl3/" target=
"table" rid-ob="ob-tbl3" rid-figpopup="tbl3" class=
"table img_link icnblk_img figpopup"><img alt="Table 3" title=
"Table 3" class="small-thumb" src=
"/pmc/articles/PMC1884989/table/tbl3/?report=thumb" src-large=
"/pmc/articles/PMC1884989/table/tbl3/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC1884989/table/tbl3/" target="table" rid-figpopup=
"tbl3" rid-ob="ob-tbl3">Table 3</a></div>
<!--caption a4-->
<div><span>Demographics and baseline characteristics</span></div>
</div>
</div>
</div>
<div id="__sec27" class="sec">
<h4>Pharmacokinetic evaluations</h4>
<p id="__p40" class="p p-first">In study 1, concomitant use of
ketoconazole resulted in substantial increases in plasma
concentrations of quetiapine (<a href=
"/pmc/articles/PMC1884989/figure/fig03/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig03" rid-ob=
"ob-fig03" co-legend-rid="lgnd_fig03"><span>Figure 3A</span></a>).
The mean <em>C</em><sub>max</sub> and AUC of quetiapine were
increased by 235% and 522%, respectively. Conversely, the geometric
mean AUC and <em>C</em><sub>max</sub> of the sulfoxide metabolite
were decreased by 46% and 87%, respectively (<a href=
"/pmc/articles/PMC1884989/figure/fig03/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig03" rid-ob=
"ob-fig03" co-legend-rid="lgnd_fig03"><span>Figure 3B</span></a>).
Mean CL/F of quetiapine was decreased by 84%, and mean
<em>t</em>1/2 was increased from 2.61 to 6.76 h. Data for all
pharmacokinetic variables are summarized in <a href=
"/pmc/articles/PMC1884989/table/tbl4/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl4" rid-ob=
"ob-tbl4" co-legend-rid=""><span>Table 4</span></a>.</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig03"
co-legend-rid="lgnd_fig03"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC1884989/figure/fig03/" target="figure"
rid-figpopup="fig03" rid-ob="ob-fig03"><img src=
"/pmc/articles/PMC1884989/bin/bcp0061-0058-f3.gif" class=
"small-thumb" alt="Figure 3" title="Figure 3" src-large=
"/pmc/articles/PMC1884989/bin/bcp0061-0058-f3.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig03">
<div><a class="figpopup" href=
"/pmc/articles/PMC1884989/figure/fig03/" target="figure"
rid-figpopup="fig03" rid-ob="ob-fig03">Figure 3</a></div>
<!--caption a4-->
<div><span>(A) Mean ± SE plasma concentrations of quetiapine in the
absence and presence of ketoconazole (days 1 and 6). (B) Mean ± SE
plasma concentrations of quetiapine sulfoxide metabolite in the
absence and presence of ketoconazole (days 1 and</span>
<strong>...</strong></div>
</div>
</div>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl4"><a href="/pmc/articles/PMC1884989/table/tbl4/" target=
"table" rid-ob="ob-tbl4" rid-figpopup="tbl4" class=
"table img_link icnblk_img figpopup"><img alt="Table 4" title=
"Table 4" class="small-thumb" src=
"/pmc/articles/PMC1884989/table/tbl4/?report=thumb" src-large=
"/pmc/articles/PMC1884989/table/tbl4/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC1884989/table/tbl4/" target="table" rid-figpopup=
"tbl4" rid-ob="ob-tbl4">Table 4</a></div>
<!--caption a4-->
<div><span>Geometric means of the pharmacokinetic parameters for a
single dose of quetiapine administered alone and concurrently with
ketoconazole</span></div>
</div>
</div>
<p id="__p41" class="p p-last">In study 2, concomitant use of
carbamazepine resulted in substantial decreases in plasma
concentrations of quetiapine (<a href=
"/pmc/articles/PMC1884989/figure/fig04/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig04" rid-ob=
"ob-fig04" co-legend-rid="lgnd_fig04"><span>Figure 4</span></a>).
The geometric mean AUCτ-ss and <em>C</em><sub>max</sub>-ss of
quetiapine were decreased by 87% and 80%, respectively. Geometric
mean CL/F of quetiapine was increased approximately sevenfold.
Although the median <em>t</em><sub>max</sub>-ss of quetiapine was
slightly decreased in the presence of carbamazepine, this
difference was not considered statistically significant. Data for
all pharmacokinetic variables are summarized in <a href=
"/pmc/articles/PMC1884989/table/tbl5/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl5" rid-ob=
"ob-tbl5" co-legend-rid=""><span>Table 5</span></a>.</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig04"
co-legend-rid="lgnd_fig04"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC1884989/figure/fig04/" target="figure"
rid-figpopup="fig04" rid-ob="ob-fig04"><img src=
"/pmc/articles/PMC1884989/bin/bcp0061-0058-f4.gif" class=
"small-thumb" alt="Figure 4" title="Figure 4" src-large=
"/pmc/articles/PMC1884989/bin/bcp0061-0058-f4.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig04">
<div><a class="figpopup" href=
"/pmc/articles/PMC1884989/figure/fig04/" target="figure"
rid-figpopup="fig04" rid-ob="ob-fig04">Figure 4</a></div>
<!--caption a4-->
<div><span>Mean ± SE plasma concentrations of quetiapine in the
absence and presence of carbamazepine (days 9 and 34). SE, Standard
error. Day 9 (quetiapine alone) (•); Day 34 (quetiapine +
carbamazepine) (○)</span></div>
</div>
</div>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl5"><a href="/pmc/articles/PMC1884989/table/tbl5/" target=
"table" rid-ob="ob-tbl5" rid-figpopup="tbl5" class=
"table img_link icnblk_img figpopup"><img alt="Table 5" title=
"Table 5" class="small-thumb" src=
"/pmc/articles/PMC1884989/table/tbl5/?report=thumb" src-large=
"/pmc/articles/PMC1884989/table/tbl5/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC1884989/table/tbl5/" target="table" rid-figpopup=
"tbl5" rid-ob="ob-tbl5">Table 5</a></div>
<!--caption a4-->
<div><span>Geometric means of the pharmacokinetic parameters for
quetiapine used alone and in combination with
carbamazepine<sup>*</sup></span></div>
</div>
</div>
</div>
<div id="__sec28" class="sec sec-last">
<h4>Clinical effect</h4>
<p id="__p42" class="p p-first">In study 1, evaluation of effect
was not applicable because the participants were healthy men. In
study 2, in order to ensure that the patients did not relapse into
an acute psychotic reaction, in addition to clinical observations,
serial recordings of scores on the Brief Psychiatric Rating Scale
(BPRS) and the Clinical Global Impressions (CGI) scale were
determined. Because of the small number of patients and the lack of
a comparative group, only descriptive statistics were determined
and the effect of carbamazepine on clinical efficacy could not be
judged. The mean total BPRS score improved by 6 points from
baseline (before treatment) to discharge (mean baseline score 15.0;
mean discharge score 9.1). No change was seen in the CGI-Severity
of Illness score (mean baseline score 3.89; mean discharge score
3.69) and/or the CGI-Improvement score (mean discharge score
3.31).</p>
<p id="__p43" class="p p-last">Adverse events that were
spontaneously reported by patients to staff members were recorded
on the case report forms and analysed; all reported events were
consistent with the known safety profile of quetiapine and were
mild or moderate in intensity; none was serious. The most common
adverse events were dizziness and somnolence (reported by five
patients each). Other adverse events were asthenia, hypotension,
nausea and rash.</p>
</div>
</div>
</div>
<div id="__sec29" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec29title">Discussion</h2>
<p id="__p44" class="p p-first">Four quetiapine metabolites were
formed by pooled human liver microsomes: the 7-hydroxyl, sulfoxide
and N- and O-desalkyl metabolites. <em>In vivo</em> studies,
reviewed by DeVane and Nemeroff [<a href="#b13" rid="b13" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210929">13</a>], have identified at least 10 measurable
metabolites of quetiapine, although many of these are secondary
oxidative or conjugated metabolites of the primary metabolite
species seen in the <em>in vitro</em> microsomal experiments.</p>
<p id="__p45">Taken together, our <em>in vitro</em> results with
specific CYP inhibitors and the heterologously expressed CYP forms
demonstrated that CYP3A4 is a major enzyme responsible for
quetiapine metabolism, and that 7-hydroxylation, a minor metabolic
pathway <em>in vivo</em>, is also catalysed by CYP2D6. Other CYP
enzymes probably do not contribute substantially to quetiapine
clearance. However, many substrates for CYP3A4 are also CYP3A5
substrates [<a href="#b14" rid="b14" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210938">14</a>]. CYP3A5 may metabolize quetiapine
similarly to CYP3A4, although we did not specifically evaluate this
or other minor CYPs in this study.</p>
<p id="__p46">Based on the moderate inhibition by sulfaphenazole at
relatively high concentrations, a contribution to all quetiapine
metabolic pathways by CYP2C9 cannot be ruled out. However, no
inhibition of quetiapine metabolism was observed when coincubated
in human liver microsomes at concentrations that substantially
decrease the metabolism of known CYP2C9 substrates [<a href="#b8"
rid="b8" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210932">8</a>], and incubations with recombinant CYP2C9
did not form detectable metabolites.</p>
<p id="__p47">Our <em>in vitro</em> findings suggested that
concurrent administration of quetiapine with drugs that induce or
inhibit CYP3A4-mediated metabolism would be more likely to alter
quetiapine pharmacokinetics than drugs affecting other CYP enzymes.
Therefore, the two clinical studies were undertaken to determine if
the pharmacokinetics of quetiapine would be altered by concomitant
administration of strong CYP3A4 inhibitors or inducers. These
studies demonstrated that coadministration with ketoconazole or
carbamazepine substantially altered the pharmacokinetic profile of
quetiapine.</p>
<p id="__p48">Concurrent administration of quetiapine with the
CYP3A4 inhibitor ketoconazole <em>in vivo</em> increased plasma
concentrations of quetiapine, with increases in the mean
<em>C</em><sub>max</sub> and AUC exceeding twofold and fivefold,
respectively. The finding of a substantially increased AUC and
<em>C</em><sub>max</sub> is consistent with significant first-pass
metabolism and hepatic clearance of quetiapine by CYP3A4. In this
study, an 84% reduction in quetiapine clearance paralleled the
increases in both <em>C</em><sub>max</sub> and AUC. Because
quetiapine was given as a single low dose (25 mg), no adverse
events were expected in the study participants despite exposure to
increased plasma concentrations of quetiapine.</p>
<p id="__p49">Results of both clinical studies are consistent with
the <em>in vitro</em> data predicting CYP3A4 as the primary CYP
enzyme for quetiapine and with an earlier pharmacokinetic
interaction study in humans treated with phenytoin, another inducer
of CYP3A4 [<a href="#b15" rid="b15" class=
" bibr popnode">15</a>].</p>
<p id="__p50">In the quetiapine–ketoconazole interaction study
(study 1), a low dose of quetiapine was used because the study was
performed in healthy volunteers. A low dose was believed to be
scientifically appropriate because quetiapine is known to have
linear pharmacokinetics at doses approved for use in the clinic.
High doses of quetiapine in healthy volunteers are associated with
considerable sedation, with a risk of developing symptomatic
hypotension.</p>
<p id="__p51">However, in clinical practice in patients with
psychiatric illness, quetiapine is administered at substantially
higher dosages (up to 750 mg day<sup>−1</sup>) [<a href="#b16" rid=
"b16" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210928">16</a>, <a href="#b17" rid="b17" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210948">17</a>]. Ketoconazole has been shown to decrease
the clearance and thus potentially increase adverse effects
associated with many drugs that are CYP3A substrates [<a href="#b9"
rid="b9" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210935">9</a>, <a href="#b18" rid="b18" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210943">18</a>, <a href="#b19" rid="b19" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210947">19</a>], including midazolam [<a href="#b20" rid=
"b20" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210944">20</a>], triazolam [<a href="#b21" rid="b21"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210925">21</a>, <a href="#b22" rid="b22" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210941">22</a>], zolpidem [<a href="#b23" rid="b23"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210924">23</a>] and tacrolimus [<a href="#b24" rid="b24"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210946">24</a>]. Ketoconazole has also been shown to
inhibit Pgp [<a href="#b25" rid="b25" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210940">25</a>] and may cause interactions with drugs
that are Pgp substrates. In addition, Boulton <em>et
al.</em>[<a href="#b26" rid="b26" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210931">26</a>] suggested that quetiapine was a substrate
for Pgp in an <em>in vitro</em> study that assessed the stimulation
of adenosine triphosphatase activity in membranes with expressed
Pgp. We showed here using monolayer assays in cells expressing Pgp
that quetiapine is not a substrate of this transporter and
therefore the effects of ketoconazole on quetiapine
pharmacokinetics are likely to be due to inhibition of its
metabolic elimination. Therefore, plasma concentrations of
quetiapine, when administered in usual clinical doses concurrently
with ketoconazole or another strong CYP3A4 inhibitor, would be
expected to increase substantially compared with those of
quetiapine given alone. Likewise, drinking grapefruit juice during
treatment with quetiapine may be expected to increase exposure to
the drug owing to inactivation of intestinal CYP3A4 [<a href="#b27"
rid="b27" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130210933">27</a>].</p>
<p id="__p52" class="p p-last">Coadministration of carbamazepine
led to a significant decrease in the steady-state plasma
concentrations of quetiapine. These results demonstrate that
concurrent administration of quetiapine with a strong CYP3A4
inducer can lead to a significant increase in quetiapine metabolism
and, potentially, a loss of clinical efficacy. Possibly because of
the short duration of this study and the fact that patients were in
clinical remission before enrolment, no loss of quetiapine efficacy
was observed.</p>
</div>
<div id="__sec30" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec30title">
Conclusions</h2>
<p id="__p53" class="p p-first-last">The <em>in vitro</em> and
clinical studies described here demonstrate that clinically
important pharmacokinetic changes may occur when drugs that
potently modulate the expression or activity of CYP3A4 enzymes are
administered concurrently with quetiapine. Patients with severe
mental illness typically require long-term treatment with
antipsychotic medication, often in conjunction with other
psychotropic drugs [<a href="#b6" rid="b6" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_130210942">6</a>]
or with nonpsychiatric medications. In addition to ketoconazole and
carbamazepine, other drugs that induce or inhibit CYP3A4 (e.g.
rifampin, ritonavir) could affect quetiapine exposure, efficacy and
adverse event profile. If concomitant use of drugs that potently
change CYP3A4 activity is necessary in patients treated with
quetiapine, clinicians should monitor their patients for signs of
adverse effects or decreased efficacy and titrate dosages
accordingly.</p>
</div>
<div id="__ackid831440" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ackid831440title">
Acknowledgments</h2>
<div class="sec">
<p id="__p54"><em>We thank Dr Liyue Huang for providing the Pgp
results. Financial and editorial support for this work was provided
by AstraZeneca Pharmaceuticals LP</em>.</p>
</div>
</div>
<div id="__ref-listid831449" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ref-listid831449title">
References</h2>
<div class="ref-list-sec sec" id="reference-list">
<div class="ref-cit-blk half_rhythm" id="b1">1. <span class=
"citation">Markowitz JS, Brown CS, Moore TR. Atypical
antipsychotics. Part I: pharmacology, pharmacokinetics, and
efficacy. <span><span class="ref-journal">Ann Pharmacother.</span>
1999;<span class="ref-vol">33</span>:73–85.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9972387" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b2">2. <span class=
"citation">Goren JL, Levin GM. Quetiapine, an atypical
antipsychotic. <span><span class=
"ref-journal">Pharmacotherapy.</span> 1998;<span class=
"ref-vol">18</span>:1183–94.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9855315" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b3">3. <span class=
"citation">Seroquel (quetiapine fumarate, AstraZeneca
Pharmaceuticals LP, Wilmington, DE). Full prescribing information,
2004.</span></div>
<div class="ref-cit-blk half_rhythm" id="b4">4. <span class=
"citation">Prior TI, Chue PS, Tibbo P, Baker GB. Drug metabolism
and atypical antipsychotics. <span><span class="ref-journal">Eur
Neuropsychopharmacol.</span> 1999;<span class=
"ref-vol">9</span>:301–9.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10422890" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b5">5. <span class=
"citation">Tanaka E, Hisawa S. Clinically significant
pharmacokinetic drug interactions with psychoactive drugs:
antidepressants and antipsychotics and the cytochrome P450 system.
<span><span class="ref-journal">J Clin Pharm Ther.</span>
1999;<span class="ref-vol">24</span>:7–16.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10319902" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b6">6. <span class=
"citation">Brown CS, Markowitz JS, Moore TR, Parker NG. Atypical
antipsychotics: Part II. Adverse effects, drug interactions, and
costs. <span><span class="ref-journal">Ann Pharmacother.</span>
1999;<span class="ref-vol">33</span>:210–7.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10084417" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b7">7. <span class=
"citation">Bertz RJ, Granneman GR. Use of in vitro and in vivo data
to estimate the likelihood of metabolic pharmacokinetic
interactions. <span><span class="ref-journal">Clin
Pharmacokinet.</span> 1997;<span class=
"ref-vol">32</span>:210–58.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9084960" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b8">8. <span class=
"citation">Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors:
evaluation of specificities in the in vitro metabolism of
therapeutic agents by human liver microsomes. <span><span class=
"ref-journal">Drug Metab Dispos.</span> 1995;<span class=
"ref-vol">23</span>:154–8.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7720520" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b9">9. <span class=
"citation">Bjornsson T, Callaghan JT, Einolf HJ, Fischer V, Gan L,
Grimm SW, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach
RS, Roberts S, Roc A, Shah A, Snikeris F, Sullivan JT, Tweedie D,
Vega J, Walsh J, Wrighton SA. The conduct of in vitro and in vivo
drug–drug interaction studies: a Pharmaceutical Research and
Manufacturers of America (PhRMA) perspective. <span><span class=
"ref-journal">Drug Metab Dispos.</span> 2003;<span class=
"ref-vol">31</span>:815–32.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12814957" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b10">10. <span class=
"citation">Grimm SW, Dyroff MC. Inhibition of human drug
metabolizing cytochromes P450 by anastrozole, a potent and
selective inhibitor of aromatase. <span><span class=
"ref-journal">Drug Metab Dispos.</span> 1997;<span class=
"ref-vol">25</span>:598–602.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9152599" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b11">11. <span class=
"citation">Potkin SG, Thyrum PT, Alva G, Bera R, Yeh C, Arvanitis
LA. The safety and pharmacokinetics of quetiapine when
coadministered with haloperidol, risperidone, or thioridazine.
<span><span class="ref-journal">J Clin Psychopharmacol.</span>
2002;<span class="ref-vol">22</span>:121–30.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/11910256" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b12">12. <span class=
"citation">American Psychiatric Association. <span class=
"ref-journal">Diagnostic and Statistical Manual of Mental
Disorders.</span> 4. Washington, DC: American Psychiatric
Association, American Psychiatric Press; 2000. Text
Revision.</span></div>
<div class="ref-cit-blk half_rhythm" id="b13">13. <span class=
"citation">DeVane CL, Nemeroff CB. Clinical pharmacokinetics of
quetiapine: an atypical antipsychotic. <span><span class=
"ref-journal">Clin Pharmacokinet.</span> 2001;<span class=
"ref-vol">40</span>:509–22.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/11510628" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b14">14. <span class=
"citation">Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J,
Ruterbories K, Hamman MA, Hall SD, Wrighton SA. Comparative
metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
<span><span class="ref-journal">Drug Metab Dispos.</span>
2002;<span class="ref-vol">30</span>:883–91.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12124305" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b15">15. <span class=
"citation">Wong YWJ, Ewing BJ, Thyrum PT, Yeh C. The effect of
phenytoin and cimetidine on the pharmacokinetics of Seroquel.
<span><span class="ref-journal">Schizophr Res.</span>
1997;<span class="ref-vol">24</span>:200–1.</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b16">16. <span class=
"citation">McConville B, Carrero L, Sweitzer D, Potter L, Chaney R,
Foster K, Sorter M, Friedman L, Browne K. Long-term safety,
tolerability, and clinical efficacy of quetiapine in adolescents:
an open-label extension trial. <span><span class="ref-journal">J
Child Adolesc Psychopharmacol.</span> 2003;<span class=
"ref-vol">13</span>:75–82.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12804128" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b17">17. <span class=
"citation">Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA,
Guillen R, Pupo Guillen M. A study of quetiapine: efficacy and
tolerability in psychotic adolescents. <span><span class=
"ref-journal">J Child Adolesc Psychopharmacol.</span>
2001;<span class="ref-vol">11</span>:415–24.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/11838824" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b18">18. <span class=
"citation">Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects
of the antifungal agents on oxidative drug metabolism: clinical
relevance. <span><span class="ref-journal">Clin
Pharmacokinet.</span> 2000;<span class=
"ref-vol">38</span>:111–80.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10709776" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b19">19. <span class=
"citation">Albengres E, Le Louet H, Tillement JP. Systemic
antifungal agents. Drug interactions of clinical significance.
<span><span class="ref-journal">Drug Saf.</span> 1998;<span class=
"ref-vol">18</span>:83–97.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9512916" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b20">20. <span class=
"citation">Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be
avoided in patients receiving the systemic antimycotics
ketoconazole or itraconazole. <span><span class="ref-journal">Clin
Pharmacol Ther.</span> 1994;<span class=
"ref-vol">55</span>:481–5.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8181191" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b21">21. <span class=
"citation">Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is
potentially hazardous to patients receiving the systemic
antimycotics ketoconazole or itraconazole. <span><span class=
"ref-journal">Clin Pharmacol Ther.</span> 1994;<span class=
"ref-vol">56</span>(6 Part 1):601–7.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7995001" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b22">22. <span class=
"citation">von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX,
Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI.
Triazolam biotransformation by human liver microsomes in vitro:
effects of metabolic inhibitors and clinical confirmation of a
predicted interaction with ketoconazole. <span><span class=
"ref-journal">J Pharmacol Exp Ther.</span> 1996;<span class=
"ref-vol">276</span>:370–9.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8632299" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b23">23. <span class=
"citation">Greenblatt DJ, von Moltke LL, Harmatz JS, Mertzanis P,
Graf JA, Durol AL, Counihan M, Roth-Schechter B, Shader RI. Kinetic
and dynamic interaction study of zolpidem with ketoconazole,
itraconazole, and fluconazole. <span><span class="ref-journal">Clin
Pharmacol Ther.</span> 1998;<span class=
"ref-vol">64</span>:661–71.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9871431" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b24">24. <span class=
"citation">Mignat C. Clinically significant drug interactions with
new immunosuppressive agents. <span><span class="ref-journal">Drug
Saf.</span> 1997;<span class="ref-vol">16</span>:267–78.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/9113494" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b25">25. <span class=
"citation">Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW.
Interaction of common azole antifungals with P glycoprotein.
<span><span class="ref-journal">Antimicrob Agents Chemother.</span>
2002;<span class="ref-vol">46</span>:160–5.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC127000/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/11751127" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b26">26. <span class=
"citation">Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro
P-glycoprotein affinity for atypical and conventional
antipsychotics. <span><span class="ref-journal">Life Sci.</span>
2002;<span class="ref-vol">71</span>:163–9.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12031686" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b27">27. <span class=
"citation">Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH,
Fortlage LA, Brown MB, Guo W, Watkins PB. Grapefruit juice
increases felodipine oral availability in humans by decreasing
intestinal CYP3A protein expression. <span><span class=
"ref-journal">J Clin Invest.</span> 1997;<span class=
"ref-vol">99</span>:2545–53.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC508096/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/9153299" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1884989&amp;issue-id=144700&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
</div>
</div>
</div>
<!--post-content-->
<hr class="whole_rhythm no_bottom_margin" />
<div class="courtesy-note no_margin small">Articles from
<span class="acknowledgment-journal-title">British Journal of
Clinical Pharmacology</span> are provided here courtesy of
<strong>British Pharmacological Society</strong></div>
</div>
</div>
<!-- Book content --></div>
<div id="rightcolumn" class="four_col col last">
<!-- Custom content above discovery portlets -->
<div class="col6"></div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance">
<div class="try-button"><a href=
"/pmc/articles/PMC1884989/?report=reader"><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/3838809"
alt="PubReader format: click here to try" /></a></div>
<div class="format-menu">
<h2>Formats:</h2>
<ul>
<li class="selected">Article</li>
<li style="list-style: none">|</li>
<li><a href=
"/pmc/articles/PMC1884989/?report=reader">PubReader</a></li>
<li style="list-style: none">|</li>
<li class="epub-link"><a href="/pmc/articles/PMC1884989/epub/">ePub
(beta)</a></li>
<li style="list-style: none">|</li>
<li><a href="/pmc/articles/PMC1884989/pdf/bcp0061-0058.pdf">PDF
(223K)</a></li>
<li style="list-style: none">|</li>
<li><a href="#" data-citationid="PMC1884989" class=
"citationexporter ctxp">Citation</a></li>
</ul>
</div>
</div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance" class="share-buttons">
<h2>Share</h2>
<ul>
<li class="facebook"><a href=
"https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884989%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047626"
alt="Share on Facebook" /> Facebook</a></li>
<li class="twitter"><a href=
"https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884989%2F&amp;text=Effects%20of%20cytochrome%20P450%203A%20modulators%20ketoconazole%20and%20carbamazepine%20on%20quetiapine%20pharmacokinetics">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047627"
alt="Share on Twitter" /> Twitter</a></li>
<li class="gplus"><a href=
"https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884989%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047628"
alt="Share on Google Plus" /> Google+</a></li>
</ul>
</div>
<div id="ajax-portlets" data-pmid="16390352" data-aiid="1884989"
data-aid="1884989" data-iid="144700" data-domainid="279"
data-domain="brjclinpharm" data-accid="PMC1884989" data-md5=
"0a023ab6e643e87caa5200df4c3b745f"></div>
<!-- Custom content below discovery portlets -->
<div class="col7"></div>
</div>
</div>
<!-- Custom content after all -->
<div class="col8"></div>
<div class="col9"></div>
<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js">
</script> <script>
<![CDATA[
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
]]>
</script>
<div id="body-link-poppers"></div>
</div>
<div class="bottom">
<div id="NCBIFooter_dynamic">
<div class="breadcrumbs">You are here: <span id=
"breadcrumb_text"><a href="/guide/">NCBI</a> &gt; <a href=
"http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt;
<a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central
(PMC)</a></span></div>
<a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target=
"_blank" href=
"/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-04-01T09:54:11-04:00&amp;Host=ptpmc201">Write
to the Help Desk</a></div>
<div class="footer" id="footer">
<div class="subfooter"></div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/preloaderWidget.js">
</script>
<div id="external-disclaimer" class="offscreen_noflow">External
link. Please review our <a href=
"http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div>
<div id="ncbifooter" class="contact_info">
<div id="footer-contents-right">
<div id="nlm_thumb_logo"><a href="http://www.nlm.nih.gov" title=
"NLM">NLM</a></div>
<div id="nih_thumb_logo"><a href="http://www.nih.gov" title=
"NIH">NIH</a></div>
<div id="hhs_thumb_logo"><a href="http://www.dhhs.gov" title=
"DHHS">DHHS</a></div>
<div id="usagov_thumb_logo"><a href="http://www.usa.gov" title=
"USA.gov">USA.gov</a></div>
</div>
<div id="footer-contents-left"><a href=
"/About/disclaimer.html">Copyright</a> | <a href=
"/About/disclaimer.html#disclaimer">Disclaimer</a> | <a href=
"http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a>
| <a href="/guide/browsers/">Browsers</a> | <a href=
"http://www.nlm.nih.gov/accessibility.html">Accessibility</a> |
<a href="/About/glance/contact_info.html">Contact</a>
<p class="address vcard"><span class="url"><a class=
"fn url newdomain" href="http://www.ncbi.nlm.nih.gov">National
Center for Biotechnology Information</a>,</span> <span class=
"org url"><a href="http://www.nlm.nih.gov/">U.S. National Library
of Medicine</a></span> <span class="adr"><span class=
"street-address">8600 Rockville Pike</span>, <span class=
"locality">Bethesda</span> <span class="region">MD</span>,
<span class="postal-code">20894</span> <span class=
"country-name">USA</span></span></p>
</div>
</div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1">
</script> <script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/hfjs2.js">
</script></div>
</div>
</div>
<!--/.page--></div>
<!--/.wrap--></div>
<!-- /.twelve_col --></div>
<!-- /.grid -->
 <!-- BESelector tab -->
 <noscript><img alt="statistics" src=
"/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=brjclinpharm&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC1884989/&amp;ncbi_app=pmc" />
</noscript> <!-- usually for JS scripts at page bottom -->
 <!--<component id="PageFixtures" label="styles"></component>-->
 
<!-- F4FB70756FE7D821_0103SID /projects/PMC/PMCViewer@4.35 ptpmc201 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->
 <script type="text/javascript" src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/js/3879255/3728312/3818874/3821238/4064716/4072593/4064449/3921943/4070217/4065628.js"
snapshot="pmc">
</script>
</body>
</html>
